Skip to main content

Table 1 Patient characteristics

From: Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer

Case

Age range (y)

Weight (kg)

Dosage (MBq)

Dosage/Weight (MBq/kg)

Tumor location

Pathologya

TNM classification

Stage

1

80–89

43.3

142

3.3

L S3

Ade

pT1aN0M0

IA

2

70–79

56.5

166

2.9

R S6

SCC

cT3N2M0

IIIA

3

80–89

50.0

239

4.8

L S1 + 2

Ade

cT2aN0M0

IB

4

60–69

46.3

162

3.5

L S8

SCC

pT2aN0M0

IB

5

80–89

52.6

283

5.4

R S7

Ade

pT2aN2M0

IB

6

60–69

63.0

164

2.6

R S6

SCC

pT1aN0M0

IA

7

70–79

48.6

146

3.0

R S3

Ade

pT1bN0M0

IA

8

70–79

46.5

144

3.1

R S2

Ade

pT2aN1M0

IIA

9

70–79

72.4

292

4.0

R S5

SCC

pT1aN0M0

IA

10

70–79

47.4

242

5.1

R S1

Ade

cT4N2M0

IIIB

11

30–39

40.7

147

3.6

R S8

MEDC

pT1bN0M0

IA

12

70–79

45.9

294

6.4

L S9

Ade

pT1bN0M0

IA

13

50–59

50.0

239

4.8

R S1

Ade

pT1aN0M0

IA

14

60–69

65.7

276

4.2

L S1 + 2

SCC

cT4N3M1b

IV

15

50–59

60.7

294

4.8

L S5

Ade

pT2aN1M1b

IV

16

60–69

52.1

243

4.7

R S2

SCC

cT4N3M0

IIIB

17

80–89

56.2

236

4.2

R S2

Ade

pT1aN0M0

IA

18

70–79

57.4

145

2.5

R S7

LCNEC

pT2aN2M0

IB

19

70–79

78.4

242

3.1

L S1 + 2

SCC

pT1bN0M0

IA

20

50–59

60.6

242

4.0

R S1

Ade

pT1bN2M0

IIIA

21

60–69

67.2

243

3.6

L S3

Ade

pT3N1M0

IIIA

22

80–89

48.5

240

5.0

R S10

Ade

pT2bN0M0

IIA

23

60–69

64.7

243

3.8

L S10

SCC

pT3N0M0

IIB

24

70–79

51.4

242

4.7

L S9

Ade

pT2bN0M0

IIA

25

60–69

54.8

292

5.3

R S3

Ade

pT2aN0M0

IIA

26

60–69

45.9

224

4.9

L S1 + 2

Ade

pT4N0M0

IIIA

27

80–89

62.7

242

3.9

L S1 + 2

SCC

cT3N0M0

IIB

28

70–79

55.4

146

2.6

R S4

Ade

cT2bN1M1b

IV

29

60–69

59.4

239

4.0

R S2

Ade

pT2bN0M0

IIA

30

70–79

53.0

145

2.7

L S10

PC

pT2aN1M0

IIB

31

70–79

55.3

237

4.3

R S1

PC

pT1aN0M0

IA

32

70–79

50.7

146

2.9

L S4

Ade

pT1aN3M0

IIIB

33

60–69

68.8

274

4.0

R S5

Ade

cT2aN2M1

IV

34

60–69

57.2

245

4.3

R S1

SCC

cT3N2M0

IIIA

35

70–79

45.6

242

5.3

R S1

Ade

pT1aN0M0

IA

36

80–89

54.6

274

5.0

L S1 + 2

Ade

pT3N1M0

IIIA

37

70–79

46.6

146

3.1

R S3

Ade

pT1aN2M0

IIIA

38

80–89

51.4

292

5.7

R S10

LCNEC

pT2aN0M0

IIA

39

80–89

74.8

273

3.6

R S4

Ade

pT2aN0M0

IIA

40

60–69

51.9

166

3.2

R S3

Ade

cT2aN0M1b

IV

41

70–79

40.8

164

4.0

R S3

Ade

pT2aN0M0

IB

42

50–59

45.2

166

3.7

L S3

SCC

cT4N2M0

IIIB

43

50–59

61.4

266

4.3

R S7

PC

pT2aN2M1

IV

44

50–59

72.2

290

4.0

L S10

SCC

cT2bN3M0

IIIB

45

60–69

62.4

166

2.7

R S1

LCNEC

pT2aN0M0

IIA

46

60–69

54.3

274

5.1

R S8

Ade

pT1aN0M0

IA

47

70–79

59.4

164

2.8

R S3

SCC

pT2aN0M0

IB

48

60–69

65.6

239

3.6

L S3

Ade

pT2aN1M0

IIA

49

70–79

61.9

292

4.7

R S3

SCC

pT1bN2M0

IIIA

50

60–69

60.9

290

4.8

R S6

ASCC

pT1aN1M0

IIA

  1. aAde adenocarcinoma, SCC squamous cell carcinoma, ASCC adenosquamous carcinoma, PC pleomorphic carcinoma, MEDC mucoepidemoid carcinoma, LCNEC large cell neuroendocrine carcinoma